Biological Modeling

Contact us

Lab-in-the-loop drug discovery: wet-lab biology and AI, on a single platform

Tempus pairs one of the largest libraries of patient-derived tumor organoids with proprietary multimodal real-world data, so every hypothesis is tested in models that are grounded in patient biology—and every wet-lab finding sharpens the next dry-lab analysis.

Tempus Loop

Tempus Loop runs on the same molecular basis: every Tempus organoid is profiled with Tempus xT (DNA) and Tempus xR (RNA)—the same assays that fuel our real-world multimodal data. Our collaborations iterate in a virtuous “loop” from modeling to RWD and RWD to modeling to validate targets with the highest level of biological context.

Glowing circle connecting 'MULTIMODAL RWD,' 'PATIENT-DERIVED ORGANOIDS,' and 'AI-POWERED ANALYTICS.'

Modeling → RWD

  1. Screen investigational agents against organoids spanning a range of indications

  2. Generate hypotheses for indication, biomarker, MoA, and resistance

  3. Reflect findings back into Tempus' real-world data to size the responder population, link biomarker expression to outcomes and simulate comparator arms in real-time

Glowing ring connecting Multimodal R&D, Patient-Derived Organoids, and AI-Powered Analytics.

RWD → Modeling

  1. Identify subpopulations and biomarkers of interest in real-world data

  2. Validate key insights in matched, sequenced patient-derived organoids using CRISPR, Perturb-seq, and 3D drug response screens

  3. Stress-test biological rationale for all targets based on wet-lab experiments and real-world molecular datasets

Glowing circle, dark background, with text: "MULTIMODAL R&D", "PATIENT-DERIVED ORGANOIDS", "AI-POWERED ANALYTICS".

Built for continuity

 

Lab-in-the-loop only works when wet-lab and dry-lab signals are directly comparable and at a robust scale to generate statistical significance. Tempus has scaled its Loop Platform and runs the same NGS on organoids and at an unmatched scale.

  • 1K+ patient-derived organoids across 16+ solid tumor types

  • Every organoid profiled with Tempus xT and xR: directly comparable to patient data

  • 400k+ multimodal cases to inform which patients to model

  • No PDXs or PDXOs in screens: all organoid models are derived from patient tissue

Proof in outcomes

One of the most important things about how we’re leveraging patient-derived organoids [in the partnership] is that at the end of the day, you’re getting as close to the patients that you’re trying to treat.

—Neil Bence, PhD, Senior Vice President, Protein Homeostasis Thematic Research Center, Bristol Myers Squibb

We are excited to collaborate with Tempus, a leader in AI and precision medicine, capable of conducting end-to-end translational research from preclinical to clinical stages.

—Chan-Hee Park, CTO, JW Pharmaceutical

Patient-derived organoid screens

A portfolio of fixed and custom panels—supporting small molecules, mAbs, ADCs, T-cell engagers, BITEs, and cell therapies, with or without HLA-matched PBMCs:

  • Pan-indication
    PanCancer (30 or 60 PDOs across solid tumor types)

  • Biomarker-focused
    PanKRAS, PanPIK3CA, PanMSI-H, PanMTAP, and ADC target panels (HER2, TROP2, Nectin-4, FRα)

  • Indication-focused
    PanLung, PanCRC, PanBreast, PanOvarian, PanPanc, PanH&N

  • Custom builds
    Matched to your target product profile

Two ways to partner

  • Tempus Loop
    Full target ID and validation, RWD through CRISPR through hit validation

  • Tailored screens for your goals
    Run fixed panel screens or customize screening projects to your scientific question

This is AI-enabled precision medicine

This is the future of healthcare.